

Brain Tumor cases most oftenly related to Chronic Epilepsy

MUHAMAD THOHAR ARIFIN, ZAINAL MUTTAQIN, ERIE ANDAR, YURIZ BAKHTIAR, DODY PRIAMBADA, HAPPY KURNIA, AJID RISDIANTO, GUNADI KUSNARTO

ABSTRACT

Aim: There has been an increase in Neurosurgical procedures for epilepsy treatment, with some degree of benefits, specifically when it comes to epilepsies that are partial or localisation-related. Mesial temporal sclerosis (MTS) and primary brain tumour, as well as vascular abnormalities and malformations of cortical development (MCDs) are the main pathological entities in lesional epilepsies. After surgery, discussion was held on the histopathology and elimination of seizure.

Method: The patients were uncontrollable medically, and between July 1999 and April 2016 had to be admitted to the epilepsy surgery. Included among the preoperative evaluation protocol we performed are physical and neurological, as well as psychiatric, and neuropsychological examinations. We also performed scalp electroencephalogram (EEG), and not less than 0.5T magnetic resonance imaging (MRI). Intra operative electrocorticography (ECoG) was used to detect irritating lesion. Regular pathology was performed studies on resected specimens with further studies made on the hippocampus.

Results: Our surgery experiences based on partial epilepsy cases numbering more than 487 revealed that in 27 cases primary brain tumour presence was the responsible pathology linked to the chronic intractable epilepsy. Elimination of seizures revealed that Class 1 was seizure free in 22 cases. Class 2, on its part, revealed that not more than 2 seizures take place every year in 3 cases, and Class 3 revealed reduction in seizure frequency of above 75% in 2 cases.

Conclusions: In long-lasting epilepsy cases, tumorous lesions presence should not be ignored, while the major purpose of surgery is seizure elimination and not just the removal of tumour.

Keywords: brain tumour, epilepsy, electroencephalography

INTRODUCTION

The manifestation of seizures brought about by brain tumours comes often in the form of focal seizures by way of or short of secondary generalization, and close to one third of patients are resistant to antiepileptic medication treatment. Several possible reasons could account for such resistance to medication¹. Several important roles that seizures play in the general well-being of individuals, especially in the life of patients whose primary brain tumours are slow-growing abound^{2,3}. The tumour-related epileptogenesis have continued to be poorly understood, in spite of the fact that this subject is very important to the scientific area of neurology and neurosurgery, as well as in the field of neurooncology. The increased application of neurosurgical procedures for the epilepsy treatment has had beneficial effects, especially epilepsies that are partial or localization-related. The launching of magnetic resonance imaging (MRI) in epilepsy has very much influenced these recent advances⁴. Mesial temporal sclerosis (MTS) and primary brain tumour, as well as vascular anomaly and malformations of cortical development

(MCDs) are all part of the major pathological entities in lesional epilepsies. Patients whose epilepsy is tumour related were all given referral due to the long-lasting epilepsy and the histopathology, together with seizure elimination after discourse on surgery was undertaken.

MATERIAL AND METHOD

Between July 1999 and April 2016, the patients were admitted to the epilepsy surgery. These epilepsy patients become surgical candidates if they are seen as medically intractable or if the seizures they had are considered to be lesion related. We utilised scalp electroencephalogram (EEG) with invasive recordings that are limited, in carrying out our evaluation. EEGs were attached to patients during their sleeping and waking moments. Physical and neurological, as well as psychiatric and neuropsychological examinations were among the preoperative evaluation protocol we conducted. Every patient has had not less than 0.5T magnetic resonance imaging (MRI) scans conducted in axial and coronal, as well as sagittal planes, slices of 5-mm at T1, T2, and fluid attenuated inversion recovery (FLAIR) classifications. The Wechsler Adult Intelligence Scale were used for the standard

¹Department of Neurosurgery, Faculty of Medicine Diponegoro University / Dr Kariadi Hospital, Semarang, Indonesia
Correspondence to Dr. Muhammad Thohar Arifin, Email: thohar@fk.undip.ac.id

neuropsychological tests for the past two years. The conducting of the Wada test or intracarotid amobarbital procedure was only on selected cases. The patients received referral for surgery if concordant data were revealed in all preoperative investigations, in the absence of which, they were either scheduled to be either re-evaluated or were recommended to undergo other alternative treatments

The removal of tumour alone is not a guarantee of good result in seizure control. This is based on the assumption that neurons surrounding the tumour make up the epileptogenic zone. Nonetheless, the same argument can also be raised in the case of irritating lesion removal. Intra operative Electro Corticography (EcoG) (picture 1) was utilised in detecting Irritating lesion. The recording of intra operative Electro Corticography (EcoG) used a series of electrodes spaced evenly and embedded in the silicone plastic's "strips" or "grids". The sizes of grids and strips are standard and pre-set, but it is possible to have them trimmed for the purpose of accommodating the size and shape of the cortical surface that is exposed. Every diameter of the contact electrode is standard at 5 mm. The distance between the electrodes is also standard at 1 cm. The standard monitoring time is 5 minutes and can run up to 30 minutes while having longer recordings possess increased sensitivity in the detection of uncommon happenings. Identification of abnormal signal can be made in the operating room by way of visual observations by an epileptologist. There are variations when it comes to the recordings of pre-resection and post-resection ECoG usage. The aim of performing the two is for the identification/confirmation of seizure foci, as well as in determining the degree of resection. Monitoring and analysis of rate and location, together with the period of beginning of the observed spikes are made. Surgeons are given encouragement for minimisation of the residual tumour volume whenever it is deemed possible.

Standard pathology studies were carried out on resected specimens and further studies were also carried out on the hippocampus.

There was maintenance of AED medication, postoperatively, for a period from six months to one year in every patient, which was later reduced with the patient's consent. Re-evaluation of EEG recordings was made after a period of 6 months and every year.

RESULTS

The experiences we acquired based on more than 467 surgery cases of partial epilepsy revealed

primary brain tumour presence as the responsible pathology relative to 27 cases in long-lasting intractable epilepsy of which 11 and 16 were with females and males respectively (Table 1). They were made up of 10 cases and 17 cases of vascular hamartomas and Cortical Developments Malformations or Cortical Dysplasias respectively (picture 2). Their ages range from 14-41 years old averaging 24.3 ± 7.17 years. The ages at the first epilepsy seizure was from 2-30 years old, averaging 7.7 ± 4.70 years. The time period of epilepsy was from 1-16 years, averaging 7.7 ± 4.70 years. Electroencephalography was utilised to make evaluations in all cases intra-operatively. The studies in Histopathology revealed 9 cases to be Dysembryoplastic Neuroepithelial Tumour (DNT), and 7 cases to be Ganglioglioma, while 2 cases were Pilocytic Astrocytoma and 3 cases (2 of them revealing later changes in malignancy) of Low Grade Diffuse Astrocytoma. There were also 2 cases of Tuberous Sclerosis Complex and 2 cases of Epidermoid, as well as a case of Pleomorphic Xanthoastrocytoma (Table 2). Seizure Eliminations revealed that 22 cases in Class 1 were Seizure Free and 3 cases in Class 2 were having 2 or less seizures every year while 2 cases in Class 3 had more than 75% reduction in the frequency of seizures (Table 3).

Table 1. Demographic brain tumor with epilepsy cases

| | |
|---|-------------------------------|
| Female | 11 |
| Male | 6 |
| age | |
| The average age at the first epilepsy seizure | 24.3 ± 7.17 (14-41) years |
| The duration of having epilepsy | 14.0 ± 7.13 (2-30) years |
| | 7.7 ± 4.70 (1-16) years |

Table 2. Patological finding


| | |
|---|---|
| Dysembryoplastic Neuroepithelial Tumor (DNT) | 9 |
| Ganglioglioma | 7 |
| Pilocytic Astrocytoma | 2 |
| Low Grade Diffuse Astrocytoma (2 of them showed malignant changes later), | 3 |
| Tuberous Sclerosis Complex | 2 |
| Epidermoid | 2 |
| Pleomorphic Xanthoastrocytoma | 1 |

Table 3. Seizure elimination

| | |
|---|----------|
| Class 1 (Seizure Free) | 22 (81%) |
| Class 2 (not more than 2 seizures per year) | 3 (11%) |
| Class 3 (decrease of seizure frequency more than 75%) | 2 (8%) |

Picture 1. Intra operative EEG recording. Electrode paced upon the assumed area decided by extra cranial EEG

corelated to MRI Finding. (A)Intra operative EEG recording, irritative zone marked by green line. (B) Blue line resection area.



A

B









Fig.2: .A. Magnetic resonance imaging(MRI) showed mass occupyin g right hippocampus on 32 years old female present with complex partial seizure. 2.B. DNT showed at inferior temporal gyrus on 14 years old male present with compleks partial seizure.

A. F 23, mass occupying right hippocampus



B. M 14, DNT at inferior temporal gyrus



DISCUSSION

It is common for patients suffering from low-grade tumours like dysembryoblastic neuroepithelial tumours (DNETs) and gangliogliomas (GGs), together with oligodendrogliomas (OGs) to have seizures. These are identical to the series in our cases where cortical developmentmalformation happened to be the most frequent tumour. There is lowerepilepsyincidencein high-grade brain tumours

like glioblastoma multiformes (GBMs) and metastatic tumours. There is the likelihood of seizure development pathogenesis being different from brain tumours having histology that is different^{5,6}. Developmental tumours are made up of well-differentiated cells that have the ability of releasing neurotransmitters and other modulators involved in epileptogenesis⁷. There is the possibility of these tumours being linked to cortex structural epileptogenic abnormalities. There is also the possibility of subcortical network vital for electrical transmission suffering damage by the fast-growing high-grade brain tumours' highly infiltrative growth⁸ while there has been suggestion of slow-growing tumours, inducing cortical regions' partial differentiation, resulting in the hypersensitivity of denervation^{7,9} and the production of an epileptogenic milieu. Furthermore, there is the possibility of changes taking place in gliosis, and chronic inflammatory within the peri-tumoral regions leading to epileptic seizures. It is possible for Brain tumours that have identical grade but differ in histology to have seizure incidences that are different.¹⁰ In addition, not all patients having identical localization and histology suffer from seizures⁵. Such is a strong suggestion of the possibility of genetic factors playing a part in the development of tumour and tumour-related epilepsy.

The endothelial cells and astrocytes are all part of the cellular components of the blood-brain barrier (BBB). Others include pericytes and neurons, together with junctional complexes. These junctional complexes are made up of the transmembrane junctional proteins that include occludin and claudins, together with junctional adhesion molecules which are formed as part of the cellular components of the BBB.¹¹ Studies of humans and animals have given suggestion of perturbations in neurovascular integrity and BBB breakdown resulting in neuronal hyper-synchronisation and epileptiform activity. Reduction in transmembrane junctional protein expression¹² and heightened vascular endothelial growth factor (VEGF) release¹³ are all relevant molecular changes in brain tumours affecting the structure and function of BBB. VEGF diffusion into the peri-tumoral brain has the possibility of aggravating the edema which surrounds the lesion. There were endothelial tight cell junctions' structural defects surrounding human gliomas which were reported by Stewart et al.¹⁴ There is suggestion by a more current study on the possibility of this being arbitrated through the transformation of the growth factor β (TGF- β) receptor. This leads to its stimulation thereby resulting in extracellular potassium activity which depends on accumulation and N-methyl-D-aspartate (NMDA) receptor-arbitrated neuronal

hyper-excitability facilitation. It is also dependent on ultimate epileptiform activity. One other study demonstrated¹⁶ the likelihood of epileptogenesis becoming reduced by TGF- β receptors blockade taking place in a living organism.

Summing up these results suggests the possibility of BBB pathological disruption in brain tumour patients contributing to seizure activity. Defining the possibility of the degree to which BBB disturbances result in seizure induction is difficult. Nonetheless, there is a general consideration that the likely causes of seizures are tumours like LGGs that lead to BBB disturbances, although they do not succeed in the destruction of the subcortical network.

On the basis of the assumption that the tumour constituting the epileptogenic zone is surrounded by neurons, removal of the tumour alone is never a guarantee that the results of seizure control will come out well. Nonetheless, it is possible to argue on the ability of microenvironment returning to normal and the surrounding neurons ceasing to discharge abnormally if there is removal of irritating lesion. Lesionectomy alone produced very good results for majority of surgical series where paediatric patients were involved.^{17, 18} Nonetheless, studies on adult patients revealed the possibility of gross total resection or even extended lesionectomy greatly improving seizure prognosis.^{10, 19} This is in line with the findings we made of extended lesionectomy having the ability of improving seizure free after surgery. Shorter seizure history and less permanent secondary changes opportunity like hippocampal sclerosis can be attributed as a possible reason for the better lesionectomy results in children. Surgeons are, in general, given encouragement in seeing to it that the residual tumour volume is minimised whenever possible.

The traditional AEDs efficacy like valproic acid (VPA) and carbamazepine (CBZ) have not undergone any randomized clinical trials evaluation in patients suffering from brain tumours. Also not undergone randomized clinical trials are phenytoin (PHT) and phenobarbital (PB). Drawing any firm conclusions based on available studies is difficult. Therefore, the basis for the decision regarding AEDs to be administered to patients suffering from brain tumours is mainly on the preference of the individual rather than on clinical evidence. Nonetheless, a quantitative and formal epidemiological study design of 12 informative studies made by Glantz and et al.²⁰ on the investigation conducted on prophylactic anticonvulsants use such as PHT or PB or VPA in patients who have primary and metastatic brain tumours revealed the absence of efficacy in the prevention of the first seizure or in the reduction of

the initial seizures' frequency. The report of Temkin also revealed that no evidence exists on the possibility of long-term treatment with PHT and CBZ providing protection against late seizures.²⁰ There are questions that still beg for answers on whether or not a traditional AED choice should be based entirely on their side effect profile.

There is a belief of VPA inhibition of epileptic discharges through the stabilisation of neuronal membranes and improvement of GABA transmission. It has the ability of inducing apoptosis and growth arrest, as well as cell diversity of tumour cells through histone deacetylase inhibition.²² A current study revealed that autophagy in glioma cells is induced by VPA with such action being independent of apoptosis.²³ There is indication regarding the study of Weller et al. on the VPA potential anti-tumour activity in patients suffering from GBM who required an AED at the time of temozolomide-based chemoradiotherapy.²⁴ The fact of tumoral and peritumoral factors contributing to the tumour-related epileptopathogenesis suggesting of VPA being taken into consideration as a first line therapy in the treatment of tumour-related epilepsy.

CONCLUSIONS

The use of neurological surgery in the treatment of epilepsy has gone up, and such treatment does come with lots of benefits, precisely when it comes to partial or localisation-related epilepsies. Tumorous lesions presence must never be ignored when it comes to long-lasting cases of epilepsy. Developmental tumours are made up of well-differentiated cells that have the ability of releasing neurotransmitters and other modulators involved in epileptogenesis. There is the possibility of these tumours being linked to cortex structural epileptogenic abnormalities. Seizures are common among patients with low-grade tumours like dysembryoblastic neuroepithelial tumours (DNETs) and gangliogliomas (GGs), together with oligodendrogliomas (OGs). Well-differentiated cells that have the ability of releasing neurotransmitters and other modulators involved in epileptogenesis make up the developmental tumours. There is the possibility of these tumours being linked to cortex structural epileptogenic abnormalities. There is the possibility for Brain tumours having identical grade but different in histology to have seizure incidences that are different. Tumour removal alone is not a guarantee of good result will be obtained in seizure control. The removal of tumours, therefore, must never be the major purpose for patients to undergo surgery but for the elimination of seizures.

REFERENCES

1. V. Salanova, O. Markand, R. Worth. Temporal lobe epilepsy: analysis of failures and the role of reoperation. *Acta Neurologica Scandinavica*, 111 (2005), pp. 126-133
2. Arbol D, Gandotra P, Maqbool M, Shah A, Ahmad S. Dysembryoplastic neuroepithelial tumor: A Rare Brain Tumor Presenting With Atypical Radiological Findings. *JK Sci*. 2007;9:145-7.
3. R. Jung, S. Aull-Watschinger, D. Moser, T. Czech, C. Baumgartner, S. Bonelli-Nauer, et al. Is reoperation an option for patients with temporal lobe epilepsy after failure of surgery? *Seizure* (December) (2012), 10.1016/j.seizure.2012.11.011 pii: S1059-1311(12)00300-7 [Epub ahead of print] 8.
4. L. Jehi, R. Sarkis, W. Bingaman, P. Kotagal, I. Najm. When is a postoperative seizure equivalent to "epilepsy recurrence" after epilepsy surgery? *Epilepsia*, 51 (2010), pp. 994-1003
5. Moog U, Jones MC, Viskochil DH, Verloes A, Van Allen MI, Dobyns WB. Brain Anomalies In Encephalocraniocutaneous Lipomatosis. *Am J Med Genet A*. 2007; 143A:2963-2972. [PubMed]
6. Phi JH, Park SH, Chae JH, Wang KC, Cho BK, Kim SK. Papillary Glioneuronal Tumor Present In A Patient With Encephalocraniocutaneous Lipomatosis: Case Report. *Neurosurgery*. 2010; 67:E1165-E1169.[PubMed]
7. M.J. Hennessy, R.D. Elwes, C.D. Binnie, C.E. Polkey. Failed Surgery For Epilepsy. A Study of Persistence and Recurrence Of Seizures Following Temporal Resection. *Brain*, 123 (2000), pp. 2445-2466
8. A. Abosch, N. Bernasconi, W. Boling, M. Jones-Gotman, N. Poulin, F. Dubeau, et al. Factors Predictive Of Suboptimal Seizure Control Following Selective Amygdalohippocampectomy. *Journal of Neurosurgery*, 97 (2002), pp. 1142-1151
9. P. Ryvlin, P. Kahane. The Hidden Causes Of Surgery-Resistant Temporal Lobe Epilepsy: Extratemporal or Temporal Plus? *Current Opinion in Neurology*, 18 (2005), pp. 125-127
10. J.F. Téllez-Zenteno, L. Hernández Ronquillo, F. Moien-Afshari, S. Wiebe. Surgical Outcomes in Lesional and Non-Lesional Epilepsy: A Systematic Review and Meta-Analysis. *Epilepsy Research*, 89 (2010), pp. 310-318
11. C. Tonini, E. Beghi, A.T. Berg, G. Bogliun, L. Giordano, R.W. Newton, et al. Predictors of epilepsy Surgery Outcome: A Meta-Analysis *Epilepsy Research*, 62 (2004), pp. 75-87
12. A.M. McIntosh, R.M. Kalnins, L.A. Mitchell, G.C. Fabinyi, R.S. Briellmann, S.F. Berkovic. Temporal Lobectomy: Long-Term Seizure Outcome, Late Recurrence and Risks For Seizure Recurrence. *Brain*, 127 (2004), pp. 2018-2030
13. Chi OZ, Hunter C, Liu X, Tan T, Weiss HR. Effects of VEGF on the blood-brain barrier disruption caused by hyperosmolarity. *Pharmacology* 2008;82: 187-92.
14. Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF. Quantitative study of microvessel ultrastructure in human peri-tumoral brain tissue. Evidence for a blood-brain barrier defect. *J Neurosurg* 1987; 67:697-705.

15. Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, Tomkins O, et al. TGF-beta receptor mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. *Brain* 2007; 130:535–47.
16. Cacheaux LP, Ivens S, David Y, Lakhter AJ, Bar-Klein G, Shapira M, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. *J Neurosci* 2009; 29:8927–35.
17. Kim SK, Wang KC, Hwang YS, Kim KJ, Cho BK. Intractable epilepsy associated with brain tumors in children: surgical modality and outcome. *Childs Nerv Syst* 2001; 17:445–52.
18. Giulioni M, Galassi E, Zucchelli M, Volpi L. Seizure outcome of lesionectomy in glioneuronal tumors associated with epilepsy in children. *J Neurosurg* 2005; 102:288–93.
19. Hildebrand J, Lecaillon C, Perennes J, Delattre JY. Epileptic seizures during followup of patients treated for primary brain tumors. *Neurology* 2005; 65:212–5.
20. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000; 54:1886–93.
21. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. *Epilepsia* 2001; 42:515–24.
22. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. *Mol Cancer Ther* 2005; 4:1912–22.
23. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. *Neuro-oncol* 2010;12: 328–40.
24. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology* 2011;77:1156–64